- Home
- EMD vs PACB Comparison
EMD vs PACB Comparison
Compare EMD & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EMD | PACB |
|---|---|---|
| Founded | 2003 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 609.8M | 521.8M |
| IPO Year | 2003 | 2010 |
Fundamental Metrics
Financial Performance| Metric | EMD | PACB |
|---|---|---|
| Price | $10.49 | $1.16 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.67 |
| AVG Volume (30 Days) | 163.6K | ★ 7.3M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 10.25% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $93,468,000.00 |
| Revenue This Year | N/A | $11.32 |
| Revenue Next Year | N/A | $12.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.04 |
| 52 Week Low | $9.60 | $1.07 |
| 52 Week High | $11.30 | $2.73 |
Technical Indicators
Market Signals| Indicator | EMD | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 44.42 | 35.63 |
| Support Level | $10.47 | $1.09 |
| Resistance Level | $10.63 | $1.79 |
| Average True Range (ATR) | 0.10 | 0.09 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 30.43 | 20.24 |
Price Performance
Historical ComparisonAbout EMD Western Asset Emerging Markets Debt Fund Inc
Western Asset Emg Markets Debt Fund Inc is a non-diversified closed-end management and long term investment company. The primary investment objective of the company is to seek high current income, and the secondary objective is to seek capital appreciation.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.